Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study-INTERACT MESO

July 13, 2022 | Comments Off on Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study-INTERACT MESO

BMJ Open 2022 June 22 [Link] Job P van Kooten, Michelle V Dietz, Niels A D Guchelaar, Alexandra R M Brandt-Kerkhof, Stijn L W Koolen, Jacobus W A Burger, Ron…

Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)

July 12, 2022 | Comments Off on Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)

Langenbeck’s Archives of Surgery 2022 June 23 [Link] Miklos Acs, Michael Gerken, Ivana Gajic, Max Mayr, Jozef Zustin, Pompiliu Piso Abstract Purpose: This single-center study evaluated cytoreductive surgery (CRS) combined…

Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial

July 11, 2022 | Comments Off on Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial

EClinicalMedicine 2022 May 19 [Link] Dean A Fennell, Catharine Porter, Jason Lester, Sarah Danson, Paul Taylor, Michael Sheaff, Robin M Rudd, Aarti Gaba, Sara Busacca, Lisette Nixon, Georgina Gardner, Liz…

Primary malignant pericardial mesothelioma with a survival of 2.5 years: a case report

July 8, 2022 | Comments Off on Primary malignant pericardial mesothelioma with a survival of 2.5 years: a case report

Translational Cancer Research 2022 May [Link] Yan Yan, Wenli Lv, Yinghao Luo, Jianlin Hu, Jie Yang Abstract Background: Primary malignant pericardial mesothelioma (PMPM) is a highly malignant tumor originating in…

Repurposing therapeutics for malignant pleural mesothelioma (MPM) – Updates on clinical translations and future outlook

July 7, 2022 | Comments Off on Repurposing therapeutics for malignant pleural mesothelioma (MPM) – Updates on clinical translations and future outlook

Life Sciences 2022 June 13 [Link] Nishant S Kulkarni, Vivek Gupta Abstract Introduction: Malignant pleural mesothelioma (MPM) is a rare malignancy affecting the mesothelial cells in the pleural lining surrounding…

The health effects of short fiber chrysotile and amphibole asbestos

July 6, 2022 | Comments Off on The health effects of short fiber chrysotile and amphibole asbestos

Critical Reviews in Toxicology 2022 June 15 [Link] David M Bernstein Abstract The potential toxic effects of short chrysotile and amphibole asbestos fibers with lengths <5 to ∼10 µm have…

Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape

July 5, 2022 | Comments Off on Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape

JCO Precision Oncology 2022 June [Link] Ibiayi Dagogo-Jack, Russell W Madison, Jochen K Lennerz, Kuei-Ting Chen, Julia F Hopkins, Alexa B Schrock, Lauren L Ritterhouse, Ashley Lester, Keith A Wharton…

Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma

June 30, 2022 | Comments Off on Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma

Balkan Medical Journal 2022 June 13 [Link] Muzaffer Metintaş, Güntülü Ak, Cansu Özbayer, Filiz Boğar, Selma Metintaş Abstract Background: miRNAs are involved in tumor pathogenesis and can therefore be determined…

YAP1 is essential for malignant mesothelioma tumor maintenance

June 30, 2022 | Comments Off on YAP1 is essential for malignant mesothelioma tumor maintenance

BMC Cancer 2022 June 10 [Link] Loreley Calvet, Odette Dos-Santos, Emmanuel Spanakis, Véronique Jean-Baptiste, Jean-Christophe Le Bail, Armelle Buzy, Pascal Paul, Christophe Henry, Sandrine Valence, Colette Dib, Jack Pollard, Sukhvinder…

Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma

June 29, 2022 | Comments Off on Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma

The Oncologist 2022 June 7 [Link] Yutaka Fujiwara, Yasuo Takahashi, Morihito Okada, Takumi Kishimoto, Shunsuke Kondo, Koshi Fujikawa, Manabu Hayama, Masatoshi Sugeno, Shinya Ueda, Keiko Komuro, Mark Lanasa, Takashi Nakano…

Categories